感染、炎症、修复
感染、炎癥、脩複
감염、염증、수복
INFECTION， INFLAMMATION， REPAIR
2014年
1期
18-22
,共5页
邹吉平%黄沙%宣敏%程飚
鄒吉平%黃沙%宣敏%程飚
추길평%황사%선민%정표
骨髓间充质干细胞%糖尿病创面%炎症细胞%趋化因子
骨髓間充質榦細胞%糖尿病創麵%炎癥細胞%趨化因子
골수간충질간세포%당뇨병창면%염증세포%추화인자
Bone marrow stem cells%Diabetes wound%Inflammatory cells%Chemokine
目的：观察骨髓间充质干细胞(BMSCs)对糖尿病小鼠(db/db)创面中性粒细胞(PMNs)和巨噬细胞(MΦ)浸润及巨噬细胞炎性蛋白-2(MIP-2)和单核细胞趋化蛋白-1(MCP-1)mRNA 表达的影响。方法：40只C57BLKS/Nju背景自发突变糖尿病雄性小鼠(db/db小鼠)随机分为BMSCs治疗组和对照组(n=20),均于背部制作2个0.8 cm×0.8 cm全层皮肤缺损创面模型。BMSCs治疗组于伤后当天(第0天)向全层皮肤缺损创缘皮下注射BMSCs 1×106个,对照组同法注射等体积PBS。IPP6.0图像分析软件测算创面形成后第1、3、5、7、10、14天创面愈合率；免疫组化染色后采用 IPP6.0病理图像分析软件测定吸光度值检测伤后第1、3、5、7、10天创面PMNs和第3、5、7、10、14天 MΦ浸润情况；用 qRT-PCR 相对定量法检测第1、3、5、7天创面组织中趋化因子MIP-2和 MCP-1 mRNA的表达。结果：BMSCs 治疗组和对照组的创面愈合时间分别为(11.67±0.58)d 和(16.33±0.58)d(P<0.05)。BMSCs治疗组PMNs和 MΦ浸润高峰均较对照组提前,且高峰值增高(P<0.01)；BMSCs组 MIP-2 mRNA表达高峰在创伤后第1天,为对照组30.91倍(P<0.05),MCP-1 mRNA表达高峰在创伤后第3天,为对照组96.88倍(P<0.05)。结论：BMSCs 可能通过提高创伤部位趋化因子 MIP-2和 MCP-1表达进而促进早期炎症细胞P MN s和 MΦ浸润,改善糖尿病创面愈合。
目的：觀察骨髓間充質榦細胞(BMSCs)對糖尿病小鼠(db/db)創麵中性粒細胞(PMNs)和巨噬細胞(MΦ)浸潤及巨噬細胞炎性蛋白-2(MIP-2)和單覈細胞趨化蛋白-1(MCP-1)mRNA 錶達的影響。方法：40隻C57BLKS/Nju揹景自髮突變糖尿病雄性小鼠(db/db小鼠)隨機分為BMSCs治療組和對照組(n=20),均于揹部製作2箇0.8 cm×0.8 cm全層皮膚缺損創麵模型。BMSCs治療組于傷後噹天(第0天)嚮全層皮膚缺損創緣皮下註射BMSCs 1×106箇,對照組同法註射等體積PBS。IPP6.0圖像分析軟件測算創麵形成後第1、3、5、7、10、14天創麵愈閤率；免疫組化染色後採用 IPP6.0病理圖像分析軟件測定吸光度值檢測傷後第1、3、5、7、10天創麵PMNs和第3、5、7、10、14天 MΦ浸潤情況；用 qRT-PCR 相對定量法檢測第1、3、5、7天創麵組織中趨化因子MIP-2和 MCP-1 mRNA的錶達。結果：BMSCs 治療組和對照組的創麵愈閤時間分彆為(11.67±0.58)d 和(16.33±0.58)d(P<0.05)。BMSCs治療組PMNs和 MΦ浸潤高峰均較對照組提前,且高峰值增高(P<0.01)；BMSCs組 MIP-2 mRNA錶達高峰在創傷後第1天,為對照組30.91倍(P<0.05),MCP-1 mRNA錶達高峰在創傷後第3天,為對照組96.88倍(P<0.05)。結論：BMSCs 可能通過提高創傷部位趨化因子 MIP-2和 MCP-1錶達進而促進早期炎癥細胞P MN s和 MΦ浸潤,改善糖尿病創麵愈閤。
목적：관찰골수간충질간세포(BMSCs)대당뇨병소서(db/db)창면중성립세포(PMNs)화거서세포(MΦ)침윤급거서세포염성단백-2(MIP-2)화단핵세포추화단백-1(MCP-1)mRNA 표체적영향。방법：40지C57BLKS/Nju배경자발돌변당뇨병웅성소서(db/db소서)수궤분위BMSCs치료조화대조조(n=20),균우배부제작2개0.8 cm×0.8 cm전층피부결손창면모형。BMSCs치료조우상후당천(제0천)향전층피부결손창연피하주사BMSCs 1×106개,대조조동법주사등체적PBS。IPP6.0도상분석연건측산창면형성후제1、3、5、7、10、14천창면유합솔；면역조화염색후채용 IPP6.0병리도상분석연건측정흡광도치검측상후제1、3、5、7、10천창면PMNs화제3、5、7、10、14천 MΦ침윤정황；용 qRT-PCR 상대정량법검측제1、3、5、7천창면조직중추화인자MIP-2화 MCP-1 mRNA적표체。결과：BMSCs 치료조화대조조적창면유합시간분별위(11.67±0.58)d 화(16.33±0.58)d(P<0.05)。BMSCs치료조PMNs화 MΦ침윤고봉균교대조조제전,차고봉치증고(P<0.01)；BMSCs조 MIP-2 mRNA표체고봉재창상후제1천,위대조조30.91배(P<0.05),MCP-1 mRNA표체고봉재창상후제3천,위대조조96.88배(P<0.05)。결론：BMSCs 가능통과제고창상부위추화인자 MIP-2화 MCP-1표체진이촉진조기염증세포P MN s화 MΦ침윤,개선당뇨병창면유합。
Objective:To study the effect of bone marrow mesenchymal stem cells (BMSCs)on infiltration of neutrophils (PMNs)and macrophages (MΦ),mRNA expression of macrophage inflammatory protein-2 (MIP-2),and monocyte chemo-tactic protein-1 (MCP-1)in a genetical modification-induced spontaneous diabetic murine model. Methods:Forty C57BLKS/Nj u spontaneous mutation resulted diabetic mice (db/db mice)were randomly divided into two groups:BMSCs group and control group (n=20).Full-thickness skin defects of 8 mm×8 mm were created on the dorsum of each mouse. Mice in BM-SCs group were treated with 1×106 BMSCs via subcutaneous injection around the defect after injury,but in control group, PBS was injected instead of BMSCs. Wound healing rate was assayed on postwound day 1,3,5,7,10 and 14 with image pro-cessing software IPP6.0. The infiltration of PMNs (postwound day 1,3,5,7 and 10)and MΦ(postwound day 3,5,7,10 and 14)was observed by immunohistochemical method and optical density value detection. The relative quantitative mRNA expression of MIP-2 and MCP-1 of the wound tissues on postwound day 1,3,5 and 7 was determined by qRT-PCR relative quantitative analysis.Results:The wound healing time was (11.67±0.58)days and (16.33±0.58)days respectively in BM-SCs group and PBS group (P<0.05).Infiltration of PMNs and MΦwas more marked in BMSCs group(P<0.01),with earlier peaking than in PBS group. mRNA expression of MIP-2 and MCP-1 in BMSCs group was statistically elevated in postwound day 1 and day 3,respectively (P<0.05 ),which were 30.91 and 96.88 times of those in the control group.Conclusions:BMSCs might enhance infiltration of PMNs and MΦby promoting the expression of MIP-2 and MCP-1 in wound,and they might also contribute to accelerate healing process of diabetic wound when treated with BMSCs.
